Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.
about
Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic ReviewMedical Management of Drug-Resistant TuberculosisExtensively drug-resistant tuberculosis: epidemiology and managementRecent developments in the diagnosis and management of tuberculosis.Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?Reduced virulence of an extensively drug-resistant outbreak strain of Mycobacterium tuberculosis in a murine modelHigh frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated South African patients with extensively drug-resistant tuberculosisPropensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant TuberculosisNew anti-tuberculosis drugs and regimens: 2015 updateCombined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.New antimycobacterial agents in the pre-clinical phase or beyond: recent advances in patent literature (2001-2016).Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosisA Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant TuberculosisTrends in hospital admissions at a Department for Infectious Diseases in Italy from 1995 to 2011 and implications for health policiesRedefining multidrug-resistant tuberculosis based on clinical response to combination therapy.High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, IndiaMultidrug-resistant tuberculosis around the world: what progress has been made?Towards tuberculosis elimination: an action framework for low-incidence countriesSystematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.The Non-Essential Mycolic Acid Biosynthesis Genes hadA and hadC Contribute to the Physiology and Fitness of Mycobacterium smegmatisA new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium.Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effectiveThe multidrug-resistant tuberculosis threat: old problems and new solutionsPotential of Zanthoxylum leprieurii as a source of active compounds against drug resistant Mycobacterium tuberculosis.The top-cited systematic reviews/meta-analyses in tuberculosis research: A PRISMA-compliant systematic literature review and bibliometric analysis.Evolution of Mycolic Acid Biosynthesis Genes and Their Regulation during Starvation in Mycobacterium tuberculosis.Drug resistance characteristics and cluster analysis of M. tuberculosis in Chinese patients with multiple episodes of anti-tuberculosis treatmentThe challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: a report of three cases.Bedaquiline: A Novel Antitubercular Agent for the Treatment of Multidrug-Resistant Tuberculosis.Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova.Updated diagnosis and treatment of childhood tuberculosis.Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis.Totally drug-resistant tuberculosis and adjunct therapies.Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.Bedaquiline for the treatment of drug-resistant tuberculosis.Management of drug resistantTB in patients with HIV co-infection.Synthetic investigational new drugs for the treatment of tuberculosis.
P2860
Q26764847-42A13083-C8A9-4544-BAA1-5C7F9F972F70Q26801601-ADA957DF-F1F3-41E2-B698-EFBA659465F2Q26830094-81EA12E0-51B1-4DAF-BB16-8DFE4749D8D1Q28077124-65A6B1DD-1757-4D66-ADBE-67479A2837A0Q28393235-A6A54489-C245-4AB4-8660-D939017A7DBDQ28537876-666FEF21-9A0C-47F4-8D3F-D652A147C013Q28546682-FEFAC622-1161-42E3-BEBD-2503A05D91DBQ28551033-5D985573-F4E1-43A5-81B1-7B07D732300EQ28596775-BFF263FA-D4BA-4CC7-86D3-140BB6ED715FQ30236048-FE3B277D-2B7C-4671-ACC8-1B86B385B593Q30243915-D015263F-373B-43C9-8A2E-F6473EDFFABDQ30275673-197DB96F-B760-4B21-BB4F-2D9838443EF9Q33926262-EDFAC710-8098-4C29-BCB3-F2737FBB7EADQ33939074-2FDE44CE-3743-4FA2-B825-CC8166E6D7C2Q34267435-1737351E-AC9B-4E66-A231-AE6BDD23F73FQ34298988-F3867454-C88B-4814-8504-12A16DE73AFAQ35032535-91EE499F-A934-4C45-BD75-812057E29B99Q35054224-103287B3-F961-49D6-AF9F-E75FD98F7821Q35344151-81507819-4762-498B-9BCC-1A86FB9364B2Q35568367-3EAFCC20-6F68-49D1-A05E-1156351CDA61Q35877895-AB5E21F5-0337-4418-81E2-101F036F1A0DQ35909311-35921F26-686F-44CC-9CF6-55404E60F9CDQ36021294-35886F01-E6BB-4072-8900-48B4C6070059Q36138237-6DA35BFE-58A3-4EC0-8F66-FA3ADF498974Q36266759-9EEDAB26-CE2C-4853-8620-051B7A2A6D3DQ36273950-D29E8AFE-1855-47C2-A600-4A11215993CAQ36297481-F698DEAB-F1FC-4156-8B2C-BE10175046E6Q36439741-AE875F87-C9D8-46C7-BF32-96F2D79983AAQ36490639-BD46638D-B728-41C7-8A88-213C1DE6BA2EQ37266676-2D51F301-216D-4F43-89C3-B5B09C881858Q37335803-2C09BAA7-EF37-4F57-89B9-306B1F876F41Q37733149-4DC108FA-E89D-445C-A352-8E290438D652Q38079733-D85AFC41-64C1-429F-9F7F-B426025F24D8Q38203355-4B404665-3D30-40DB-9A4F-E18AE22D70F7Q38210265-D80517A8-0E53-438C-8325-61830569DD5FQ38261230-1CA9590F-3DF3-4452-8787-75C84BDC5DE4Q38341918-61588133-98AB-4225-931D-EFF0BBFF4075Q38386950-4402830B-6E2B-4FFC-89EA-BB1EADB48B25Q38610637-B2F40049-1531-41AD-8207-E190A2BFFECEQ38635790-8B0D2AF2-3D6E-4D4E-9AA6-597959092C09
P2860
Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Drug resistance beyond extensi ...... al patient data meta-analysis.
@ast
Drug resistance beyond extensi ...... al patient data meta-analysis.
@en
type
label
Drug resistance beyond extensi ...... al patient data meta-analysis.
@ast
Drug resistance beyond extensi ...... al patient data meta-analysis.
@en
prefLabel
Drug resistance beyond extensi ...... al patient data meta-analysis.
@ast
Drug resistance beyond extensi ...... al patient data meta-analysis.
@en
P2093
P2860
P50
P921
P1476
Drug resistance beyond extensi ...... al patient data meta-analysis.
@en
P2093
A Spanevello
C Pérez-Guzmán
H S Schaaf
L D'Ambrosio
M G Hollm-Delgado
P2860
P304
P356
10.1183/09031936.00136312
P577
2012-10-11T00:00:00Z